GTx, Inc. Announces Late Breaker Presentation on Results From the Two Phase 3 POWER Trials of Enobosarm, a Selective Androgen Receptor Modulator (SARM), for the Prevention and Treatment of Muscle Wasting in NSCLC Patients During 2013 European Cancer Congr
Published: Sep 24, 2013
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today that top line results from the two Phase 3 trials (POWER1 and POWER2) on the effects of enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients will be presented on September 28, 2013, at the European Cancer Congress 2013 (September 27-October 1, 2013) in Amsterdam.
Help employers find you! Check out all the jobs and post your resume.